Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241268 | 1.00 | HRH3 (0.46) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Water SCHEMBL16161850 | 0.99 | HRH3 (0.46) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Oxalic Acid SCHEMBL1241171 | 0.96 | HRH3 (0.44) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| SCHEMBL5630601 | 0.96 | HTR7 (0.45) | HRH3HTR7TSHRALDH1A1TP53 | |
| Fumaric Acid SCHEMBL9898674 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Fumaric Acid SCHEMBL9898673 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Fumaric Acid SCHEMBL27987046 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Fumaric Acid SCHEMBL9898162 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Fumaric Acid SCHEMBL2435679 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 | |
| Fumaric Acid SCHEMBL2435682 | 0.93 | TSHR (0.41) | HRH3HTR7TSHRALDH1A1MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789102-B2 | H3 receptor antagonist for use in the treatment of alzheimer's disease | SANOFI (FR) | 2017-10-17 | — | — | US | claimed |
| EP-2833887-B1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI SA (FR) | 2016-12-28 | — | — | EP | claimed |
| US-20160256449-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-09-08 | — | — | US | claimed |
| EP-3043799-A1 | AN H3 RECEPTOR ANTAGONIST COMBINED WITH A CHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-07-20 | — | — | EP | claimed |
| EP-2445899-B1 | NOVEL FUMARATE SALTS OF A HISTAMINE H3 RECEPTOR ANTAGONIST | SANOFI SA (FR) | 2016-05-11 | — | — | EP | claimed |
| US-20160101099-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-04-14 | — | — | US | claimed |
| WO-2015032966-A1 | AN H3 RECEPTOR ANTAGONIST COMBINED WITH A CHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2015-03-12 | — | — | WO | claimed |
| CN-104363911-A | H3 receptor antagonist for treating Alzheimer disease | SANOFI SA | 2015-02-18 | — | — | CN | claimed |
| EP-2833887-A1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2015-02-11 | — | — | EP | claimed |
| US-20150031893-A1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI SA (FR) | 2015-01-29 | — | — | US | claimed |
| EP-2647377-A1 | Use of an h3 receptor antagonist for the treatment of alzheimer's disease | SANOFI (FR) | 2013-10-09 | — | — | EP | claimed |
| CN-103221394-A | Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide | SAI NUOFEI | 2013-07-24 | — | — | CN | claimed |
| US-20130137718-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-05-30 | — | — | US | claimed |
| US-20130123302-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-05-16 | — | — | US | claimed |
| CN-103068815-A | Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide | SANOFI SA | 2013-04-24 | — | — | CN | claimed |
| EP-2556064-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-02-13 | — | — | EP | claimed |
| EP-2542530-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-01-09 | — | — | EP | claimed |
| US-20120149728-A1 | NOVEL FUMARATE SALTS OF A HISTAMINE H3 RECEPTOR ANTAGONIST | SANOFI (FR) | 2012-06-14 | — | — | US | claimed |
| WO-2011109680-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2011-09-09 | — | — | WO | claimed |
| WO-2011109675-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2011-09-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101099-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | HRH3, HRH4, HRH1 | HRH3 1/4885HTR7 26/4885TSHR 270/4885 |
| US-20160256449-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | HRH3, HRH4, H1-2 | HRH3 1/4885HTR7 41/4885TSHR 435/4885 |
| US-20120149728-A1 | NOVEL FUMARATE SALTS OF A HISTAMINE H3 RECEPTOR ANTAGONIST | HRH4, HRH3, HRH2 | HRH3 2/4885HTR7 43/4885TSHR 716/4885 |
| US-20130137718-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SULT1E1, SULT2A1, STS | HRH3 2039/4885HTR7 228/4885TSHR 3886/4885 |
| US-20150031893-A1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | HRH3, HRH4, H1-2 | HRH3 1/4885HTR7 26/4885TSHR 319/4885 |
| US-20130123302-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SULT1E1, SULT2A1, STS | HRH3 2039/4885HTR7 228/4885TSHR 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.